GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Cyclically Adjusted PS Ratio

MetaStat (MetaStat) Cyclically Adjusted PS Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MetaStat Cyclically Adjusted PS Ratio Historical Data

The historical data trend for MetaStat's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Cyclically Adjusted PS Ratio Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MetaStat's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, MetaStat's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MetaStat's Cyclically Adjusted PS Ratio falls into.



MetaStat Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

MetaStat's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2018 is calculated as:

For example, MetaStat's adjusted Revenue per Share data for the three months ended in Feb. 2018 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Feb. 2018 (Change)*Current CPI (Feb. 2018)
=0/105.0520*105.0520
=0.000

Current CPI (Feb. 2018) = 105.0520.

MetaStat Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200805 0.000 91.399 0.000
200808 0.000 92.435 0.000
200811 0.000 89.624 0.000
200902 0.000 89.527 0.000
200905 0.000 90.228 0.000
200908 0.000 91.063 0.000
200911 0.000 91.272 0.000
201002 0.000 91.445 0.000
201005 0.000 92.052 0.000
201008 0.000 92.108 0.000
201011 0.000 92.315 0.000
201102 0.000 93.373 0.000
201105 0.000 95.337 0.000
201108 0.000 95.582 0.000
201111 0.000 95.449 0.000
201202 0.000 96.053 0.000
201205 0.000 96.961 0.000
201208 0.000 97.199 0.000
201211 0.000 97.133 0.000
201302 0.000 97.953 0.000
201305 0.000 98.282 0.000
201308 0.000 98.675 0.000
201311 0.000 98.334 0.000
201402 0.000 99.057 0.000
201405 0.000 100.373 0.000
201408 0.000 100.352 0.000
201411 0.000 99.635 0.000
201502 0.000 99.032 0.000
201505 0.000 100.333 0.000
201508 0.000 100.548 0.000
201511 0.000 100.135 0.000
201602 0.000 100.040 0.000
201605 0.000 101.355 0.000
201608 0.000 101.617 0.000
201611 0.000 101.829 0.000
201702 0.000 102.779 0.000
201705 0.005 103.256 0.005
201708 0.000 103.587 0.000
201711 0.000 104.072 0.000
201802 0.000 105.052 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MetaStat  (OTCPK:MTST) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


MetaStat Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of MetaStat's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Industry
Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines